Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170845869> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2170845869 endingPage "63" @default.
- W2170845869 startingPage "57" @default.
- W2170845869 abstract "A multicentre, randomised study was carried out in Europe, South Africa and North America to compare the activity and tolerability of oral versus intravenous (i.v.) topotecan in patients with relapsed epithelial ovarian cancer. Patients who had failed first-line therapy after one platinum-based regimen, which could have included a taxane, were randomised to treatment with either oral (p.o.) topotecan, 2.3 mg/m(2)/day or i.v. topotecan 1.5 mg/m(2)/day for 5 days every 21 days. Patients were stratified by prior paclitaxel exposure, interval from previous platinum therapy and tumour diameter. 266 patients were randomised. Response rates were 13% orally (p.o.) and 20% (i.v.) with a complete response in 2 and 4 patients, respectively. The difference in the response rates was not statistically significant. Median survival was 51 weeks (p.o.) and 58 weeks (i.v.) with a risk ratio of death (p.o. to i.v. treatment) of 1.361 (95% confidence interval (CI): 1.001, 1.850). Median time to progression was 13 weeks (p.o.) and 17 weeks (i.v.). The principal toxicity was myelosuppression although grade 3/4 neutropenia occurred less frequently in those receiving oral topotecan. Toxicity was non-cumulative and infectious complications were relatively infrequent. Non-haematological toxicity was generally mild or moderate. The incidence of grade 3/4 gastrointestinal events was slightly higher for oral than i.v. topotecan. Oral topotecan shows activity in second-line ovarian cancer and neutropenia may be less frequent than with the i.v. formulation. A small, but statistically significant, difference in survival favoured the i.v. formulation, but the clinical significance of this needs to be interpreted in the context of second-line palliative treatment. Oral topotecan is convenient and well tolerated and further studies to clarify its role are ongoing." @default.
- W2170845869 created "2016-06-24" @default.
- W2170845869 creator A5002518792 @default.
- W2170845869 creator A5009049651 @default.
- W2170845869 creator A5018001559 @default.
- W2170845869 creator A5028625973 @default.
- W2170845869 creator A5034539392 @default.
- W2170845869 creator A5047677453 @default.
- W2170845869 creator A5047753094 @default.
- W2170845869 creator A5063293745 @default.
- W2170845869 creator A5080571689 @default.
- W2170845869 creator A5086380281 @default.
- W2170845869 date "2002-01-01" @default.
- W2170845869 modified "2023-10-17" @default.
- W2170845869 title "A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer" @default.
- W2170845869 cites W1831044128 @default.
- W2170845869 cites W1845622004 @default.
- W2170845869 cites W1878670617 @default.
- W2170845869 cites W1905580151 @default.
- W2170845869 cites W1945760023 @default.
- W2170845869 cites W2023555639 @default.
- W2170845869 cites W2029523751 @default.
- W2170845869 cites W2088718901 @default.
- W2170845869 cites W2092998745 @default.
- W2170845869 cites W2176556095 @default.
- W2170845869 cites W4233954896 @default.
- W2170845869 doi "https://doi.org/10.1016/s0959-8049(01)00188-5" @default.
- W2170845869 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11750840" @default.
- W2170845869 hasPublicationYear "2002" @default.
- W2170845869 type Work @default.
- W2170845869 sameAs 2170845869 @default.
- W2170845869 citedByCount "90" @default.
- W2170845869 countsByYear W21708458692012 @default.
- W2170845869 countsByYear W21708458692013 @default.
- W2170845869 countsByYear W21708458692014 @default.
- W2170845869 countsByYear W21708458692015 @default.
- W2170845869 countsByYear W21708458692017 @default.
- W2170845869 countsByYear W21708458692019 @default.
- W2170845869 countsByYear W21708458692020 @default.
- W2170845869 countsByYear W21708458692021 @default.
- W2170845869 countsByYear W21708458692023 @default.
- W2170845869 crossrefType "journal-article" @default.
- W2170845869 hasAuthorship W2170845869A5002518792 @default.
- W2170845869 hasAuthorship W2170845869A5009049651 @default.
- W2170845869 hasAuthorship W2170845869A5018001559 @default.
- W2170845869 hasAuthorship W2170845869A5028625973 @default.
- W2170845869 hasAuthorship W2170845869A5034539392 @default.
- W2170845869 hasAuthorship W2170845869A5047677453 @default.
- W2170845869 hasAuthorship W2170845869A5047753094 @default.
- W2170845869 hasAuthorship W2170845869A5063293745 @default.
- W2170845869 hasAuthorship W2170845869A5080571689 @default.
- W2170845869 hasAuthorship W2170845869A5086380281 @default.
- W2170845869 hasConcept C126322002 @default.
- W2170845869 hasConcept C141071460 @default.
- W2170845869 hasConcept C197934379 @default.
- W2170845869 hasConcept C2776694085 @default.
- W2170845869 hasConcept C2777063308 @default.
- W2170845869 hasConcept C2778375690 @default.
- W2170845869 hasConcept C2778850193 @default.
- W2170845869 hasConcept C2781209748 @default.
- W2170845869 hasConcept C2781413609 @default.
- W2170845869 hasConcept C29730261 @default.
- W2170845869 hasConcept C71924100 @default.
- W2170845869 hasConcept C90924648 @default.
- W2170845869 hasConceptScore W2170845869C126322002 @default.
- W2170845869 hasConceptScore W2170845869C141071460 @default.
- W2170845869 hasConceptScore W2170845869C197934379 @default.
- W2170845869 hasConceptScore W2170845869C2776694085 @default.
- W2170845869 hasConceptScore W2170845869C2777063308 @default.
- W2170845869 hasConceptScore W2170845869C2778375690 @default.
- W2170845869 hasConceptScore W2170845869C2778850193 @default.
- W2170845869 hasConceptScore W2170845869C2781209748 @default.
- W2170845869 hasConceptScore W2170845869C2781413609 @default.
- W2170845869 hasConceptScore W2170845869C29730261 @default.
- W2170845869 hasConceptScore W2170845869C71924100 @default.
- W2170845869 hasConceptScore W2170845869C90924648 @default.
- W2170845869 hasIssue "1" @default.
- W2170845869 hasLocation W21708458691 @default.
- W2170845869 hasLocation W21708458692 @default.
- W2170845869 hasOpenAccess W2170845869 @default.
- W2170845869 hasPrimaryLocation W21708458691 @default.
- W2170845869 hasRelatedWork W1196768483 @default.
- W2170845869 hasRelatedWork W1978453679 @default.
- W2170845869 hasRelatedWork W1994125700 @default.
- W2170845869 hasRelatedWork W2020898191 @default.
- W2170845869 hasRelatedWork W2067566587 @default.
- W2170845869 hasRelatedWork W2075571760 @default.
- W2170845869 hasRelatedWork W2225907637 @default.
- W2170845869 hasRelatedWork W2247713856 @default.
- W2170845869 hasRelatedWork W2597990073 @default.
- W2170845869 hasRelatedWork W2604112126 @default.
- W2170845869 hasVolume "38" @default.
- W2170845869 isParatext "false" @default.
- W2170845869 isRetracted "false" @default.
- W2170845869 magId "2170845869" @default.
- W2170845869 workType "article" @default.